Dyne Therapeutics, Inc. · NASDAQ:DYN

Rhodes Jason P sold 384,549 Dyne Therapeutics, Inc. shares (Form 4)

Traded Apr 23 to Apr 27, 2026 · Filed Apr 27, 2026

From Apr 23 to Apr 27, 2026, Rhodes Jason P (Director) sold 384,549 Dyne Therapeutics, Inc. shares at an average US$18.47 for US$7.1M under a trading plan, leaving 1,206,026 shares. Filed Apr 27, 2026 (Form 4).

Sold
384,549 shares
Price
US$18.47 average (US$18.15 to US$19.19)
Value
US$7.1M
Holding after
1,206,026 shares (held indirectly)
Trading plan
Yes (Made under a plan set in advance)
Role
Director

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Apr 23, 2026Common StockSale19,261US$19.191,719,356Indirect
Apr 23, 2026Common StockSale38,322US$19.195,221,857Indirect
Apr 23, 2026Common StockSale377US$19.1911,286Indirect
Apr 23, 2026Common StockSale15,148US$19.191,270,556Indirect
Apr 24, 2026Common StockSale36,345US$18.481,683,011Indirect
Apr 24, 2026Common StockSale72,310US$18.485,149,547Indirect
Apr 24, 2026Common StockSale710US$18.4810,576Indirect
Apr 24, 2026Common StockSale28,583US$18.481,241,973Indirect
Apr 27, 2026Common StockSale45,709US$18.151,637,302Indirect
Apr 27, 2026Common StockSale90,943US$18.155,058,604Indirect
Apr 27, 2026Common StockSale894US$18.159,682Indirect
Apr 27, 2026Common StockSale35,947US$18.151,206,026Indirect

Source

View original at SEC

Related